Z-VAD

Name: Z-VAD
Brand: MedChemExpress
SKU: HY-164388
Rating: 5.0 (8 reviews)

Cat. No.: HY-164388 Purity: 99.20%: Data Sheet
COA

SDS
Handling Instructions
FAQs
Technical Support

Z-VAD is an irreversible, broad-spectrum pan-caspase inhibitor that can inhibit a variety of caspases including caspase-3, -6, -7, -8, -9, etc. (with a weaker inhibitory effect on caspase-2). Z-VAD can block apoptosis signaling pathways, induce autophagy and necrosis in tumor cells, and has anti-angiogenic activity. Z-VAD can enhance the sensitivity of breast cancer and lung cancer cells to radiotherapy in vitro and in vivo, and prolong the growth delay of tumor xenograft models. Z-VAD is well tolerated and is mainly used in research related to cancer radiosensitization and cell death pathway regulation.

For research use only. We do not sell to patients.

Z-VAD Chemical Structure

CAS No. : 162852-62-2

Size	Stock	Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	In-stock	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	In-stock	Estimated Time of Arrival: December 31
Solid
5 mg	In-stock	Estimated Time of Arrival: December 31
10 mg	In-stock	Estimated Time of Arrival: December 31
25 mg	In-stock	Estimated Time of Arrival: December 31
50 mg	In-stock	Estimated Time of Arrival: December 31
100 mg	Get quote
200 mg	Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 8 publication(s) in Google Scholar

8 Publications Citing Use of MCE Z-VAD

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All Caspase Isoform Specific Products:

View All Isoforms

Caspase 1 Caspase 2 Caspase 3 Caspase 4 Caspase 5 Caspase 6 Caspase 7 Caspase 8 Caspase 9 Caspase 10 Caspase 12 Caspase Caspase 11 Caspase-13

Biological Activity
Purity & Documentation
References
Customer Review

Description

IC₅₀ & Target

Caspase 3

Caspase-6

Caspase-7

Caspase-8

Caspase-9

In Vitro

Z-VAD (50 μM; 24 h) enhances the sensitivity of MDA-MB-231 breast cancer cells and H460 lung cancer cells to ionizing radiation^[1].
Z-VAD (50 μM; 24h, 48h) combined with radiotherapy induces increasing autophagosome formation in breast cancer and lung cancer cells and upregulated the expression of autophagy-related proteins such as ATG5-ATG12 complex and Beclin-1^[1].
Z-VAD (50 μM) combined with radiotherapy significantly reduces the formation of capillary-like tube structures in human umbilical vein endothelial cells (HUVECs)^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[1]

Cell Line:	MDA-MB-231 (breast cancer), H460 (lung cancer)
Concentration:	50 μM
Incubation Time:	24 h; followed by irradiation (0-6 Gy)
Result:	Significantly reduced the surviving fraction of both cell lines, with a dose enhancement ratio (DER) of 1.31, indicating increased radiosensitivity compared to radiation alone.

Western Blot Analysis^[1]

Cell Line:	MDA-MB-231 (breast cancer), H460 (lung cancer)
Concentration:	50 μM
Incubation Time:	24 h (GFP-LC3 imaging), 24 h/48 h (Western blotting); combined with 5 Gy radiation
Result:	Significantly increased punctate autophagosome formation, compared to single treatments. Upregulated the expression of ATG5-ATG12 complex and Beclin-1 proteins at 24 h and 48 h after combined treatment, indicating induction of autophagy-related pathways.

Cell Migration Assay ^[1]

Cell Line:	HUVECs (human umbilical vein endothelial cells)
Concentration:	50 μM
Incubation Time:	Pre-treatment for 24 h before seeding on Matrigel
Result:	Significantly decreased the number of capillary-like tubules formed by HUVECs on Matrigel, with an average reduction from 47.66 (control) to 6.0 tubules per microscopic field, demonstrating anti-angiogenic effects.

In Vivo

Z-VAD (5 mg/kg; intraperitoneal injection; three times a week; 4 weeks) significantly inhibits tumor growth in nude mouse MDA-MB-231 breast cancer and H460 lung cancer xenograft tumor models when combined with radiotherapy and was well tolerated^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Female BALB/c nude mice (6-8 weeks old, 18-22 g) bearing MDA-MB-231 breast cancer or H460 lung cancer xenograft tumors^[1]
Dosage:	5 mg/kg
Administration:	Intraperitoneal injection, three times a week, for 4 weeks
Result:	Treatment with 5 mg/kg Z-VAD via intraperitoneal injection three times a week for 4 weeks, combined with radiotherapy, significantly reduced the tumor volume in both MDA-MB-231 and H460 xenograft models compared to radiotherapy alone. The mice showed no significant signs of toxicity or adverse effects, indicating good tolerance to the treatment.

Molecular Weight

437.44

Formula

C₂₀H₂₇N₃O₈

CAS No.

162852-62-2

Appearance

Solid

Color

White to off-white

Sequence

Z-Val-Ala-Asp

Sequence Shortening

Z-VAD

SMILES

OC(C[C@@H](C(O)=O)NC([C@H](C)NC([C@H](C(C)C)NC(OCC1=CC=CC=C1)=O)=O)=O)=O

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Sealed storage, away from moisture

Powder	-80°C	2 years
	-20°C	1 year

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

Solvent & Solubility

In Vitro:

DMSO : 50 mg/mL (114.30 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	2.2860 mL	11.4301 mL	22.8603 mL
5 mM	0.4572 mL	2.2860 mL	4.5721 mL
10 mM	0.2286 mL	1.1430 mL	2.2860 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 5 mg/mL (11.43 mM); Clear solution

This protocol yields a clear solution of ≥ 5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (50.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (5.72 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 2.5 mg/mL (5.72 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

Purity & Documentation

Purity: 99.20%

Select Batch:

Data Sheet (278 KB) SDS (252 KB)

COA (246 KB) RP-HPLC (110 KB) MS (234 KB)

Handling Instructions (2659 KB)

References

[1]. Luigi Moretti, et al. Radiosensitization of solid tumors by Z-VAD, a pan-caspase inhibitor. Mol Cancer Ther. 2009 May;8(5):1270-9. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	2.2860 mL	11.4301 mL	22.8603 mL	57.1507 mL
	5 mM	0.4572 mL	2.2860 mL	4.5721 mL	11.4301 mL
	10 mM	0.2286 mL	1.1430 mL	2.2860 mL	5.7151 mL
	15 mM	0.1524 mL	0.7620 mL	1.5240 mL	3.8100 mL
	20 mM	0.1143 mL	0.5715 mL	1.1430 mL	2.8575 mL
	25 mM	0.0914 mL	0.4572 mL	0.9144 mL	2.2860 mL
	30 mM	0.0762 mL	0.3810 mL	0.7620 mL	1.9050 mL
	40 mM	0.0572 mL	0.2858 mL	0.5715 mL	1.4288 mL
	50 mM	0.0457 mL	0.2286 mL	0.4572 mL	1.1430 mL
	60 mM	0.0381 mL	0.1905 mL	0.3810 mL	0.9525 mL
	80 mM	0.0286 mL	0.1429 mL	0.2858 mL	0.7144 mL
	100 mM	0.0229 mL	0.1143 mL	0.2286 mL	0.5715 mL

Z-VAD Related Classifications

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Z-VAD162852-62-2CaspaseApoptosisAutophagyNecroptosiscompetitiveirreversibleradiationMDA-MB-231H460antiangiogenicInhibitorinhibitorinhibit

Your Recently Viewed Products:

Product Name

Requested Quantity *

Applicant Name *

Salutation

Email Address *

Phone Number *

Department

Organization Name *

City

State

Country or Region *

Remarks

Product Name

Lot #

Applicant Name *

Email Address *

Phone Number

Department *

Organization Name *

Country or Region *

Remarks

Name
Email *

	Sorry, but the email address you supplied was invalid.

Z-VAD

Customer Review

Z-VAD Related Antibodies

8 Publications Citing Use of MCE Z-VAD

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All Caspase Isoform Specific Products:

Biological Activity

Purity & Documentation

References

Customer Review

Z-VAD Related Antibodies

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

Z-VAD Related Classifications

Keywords:

Your Recently Viewed Products:

Customer Review

Request for HNMR Report

SAFETY DATA SHEET (SDS)

Request for HNMR Report